CHDI
Discovery research and systems biology leader joins CHDI
New York, June 2 2014: CHDI has appointed Thomas F Vogt, PhD as its new Vice President of Discovery and Systems Biology. Vogt and his group will work closely with the translational biology, chemistry, and clinical groups at CHDI to identify an ...Read More
KineMed and CHDI Foundation Extend Huntington’s Disease Collaboration
EMERYVILLE, Calif., May 19, 2014 -- KineMed, Inc. ( ...Read More
A Field Guide to Working with Mouse Models of Huntington’s Disease
Many different mouse models of Huntington’s disease are now available and the choice of which model(s) to use is a critical consideration that depends greatly on your particular research focus. Equally, good husbandry to breed and rear mouse coloni ...Read More
Huntington’s Disease Society of America endorses Enroll-HD
A statement from the Huntington's Disease Society of America New York, NY, February 21, 2014 -- The Huntington’s Disease Society of America (HDSA) is pleased to announce its endorsement of the Enroll-HD prospective registry stud ...Read More
CHDI Foundation and Genzyme enter agreement to develop novel virally delivered gene-silencing therapeutic for Huntington’s disease
New York, NY, February 21 2014 - CHDI Foundation, Inc. and Genzyme Corporation have entered into a collaboration to develop adeno-associated virus delivery of a novel gene silencing therapeutic approach for Huntington's disease. The agreed res ...Read More
Roche and Isis Pharmaceuticals form alliance for Huntington’s disease
Basel, Switzerland and Carlsbad, CA, USA Roche (SIX: RO, ROG; OTCQX: RHHBY) and Isis Pharmaceuticals, Inc (NASDAQ: ISIS) today announced that they have formed an alliance to develop treatments for Huntington’s disease (HD) based on Isis’ antis ...Read More
Huntington’s disease therapeutic and companion biomarker collaboration forged by KineMed, Isis Pharmaceuticals, and CHDI Foundation.
Emeryville, CA, KineMed, Inc., Isis Pharmaceuticals Inc. (NASDAQ: ISIS), and CHDI Foundation, Inc., announced today that they are collaborating to utilize KineMed’s translational biomarker platform with Isis’s antisense therapeutic program for H ...Read More
CHDI Foundation continues collaboration with Medtronic to advance siRNA therapeutics to treat Huntington’s disease
New York City, CHDI Foundation, Inc. has announced it will continue its collaboration with Medtronic, Inc. (NYSE: MDT) to advance a novel drug-device combination therapy for the treatment of Huntington’s disease (HD). This therapeutic approach uses ...Read More
Sangamo BioSciences announces FIRST presentation of Data from ZFP Therapeutic® for Huntington’s disease at 2012 Annual Meeting of Society for Neuroscience
Richmond, California, Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from its program with Shire AG (LSE: SHP, NASDAQ: SHPG) to develop a novel ZFP Therapeutic approach to Huntington’s disease (HD), an inherited progressive neurodegen ...Read More